Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

electroCore, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SECOND QUARTER 2026 NET SALES OF $9.5 MILLION, AN INCREASE OF 28% OVER $7.4 MILLION IN THE SECOND QUARTER 2025 NET LOSS OF $3.1 MILLION DECREASED 17% FROM PRIOR YEAR WITH ADJUSTED EBITDA NET LOSS IMPROVING 26% FROM PRIOR-YEAR PERIOD INCREASING 2026 REVENUE GUIDANCE TO GREATER THAN 30% YEAR-OVER-YEAR GROWTH COMPANY TO HOST A CONFERENCE CALL AND WEBCAST TODAY, AUGUST 6, 2026, AT 4:30 PM EDT ROCKAWAY, N.J., AUG. 06, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR) (ELECTROCORE OR THE COMPANY), A BIOELECTRONIC TECHNOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026.

ELECTROCORE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

ROCKAWAY, N.J., AUG. 03, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES:

ELECTROCORE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

ROCKAWAY, N.J., JULY 30, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AFTER THE CLOSE OF THE MARKET ON THURSDAY, AUGUST 6, 2026.

ELECTROCORE TO ANNOUNCE SECOND QUARTER JUNE 30, 2026, FINANCIAL RESULTS ON THURSDAY, AUGUST 6, 2026

ROCKAWAY, N.J., JULY 16, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY AND LEADER IN NON-INVASIVE VAGUS NERVE STIMULATION TECHNOLOGIES, TODAY ANNOUNCED THE PUBLICATION OF THE PEER-REVIEWED REVIEW ARTICLE, "TWO PATHS TO THE BODY'S SUPERHIGHWAYTHE AURICULAR BRANCH (TAVNS) AND THE CERVICAL BUNDLE (TCVNS): A NARRATIVE REVIEW," INFRONTIERS IN NEUROSCIENCE. THE ARTICLE WAS AUTHORED BY PETER S. STAATS, MD, MBA, CHIEF MEDICAL OFFICER OF ELECTROCORE, AND JUSTYNA BLAKE, SENIOR DIRECTOR OF MEDICAL AFFAIRS AT ELECTROCORE.

NEW REVIEW EXAMINES ANATOMICAL AND METHODOLOGICAL DIFFERENCES BETWEEN AURICULAR AND CERVICAL VAGUS NERVE STIMULATION

ROCKAWAY, N.J., JUNE 17, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE IACCESS ALPHA VIRTUAL BEST IDEAS SUMMER INVESTMENT CONFERENCE ON JUNE 23-24, 2026.

ELECTROCORE TO PARTICIPATE IN IACCESS ALPHA VIRTUAL BEST IDEAS SUMMER INVESTMENT CONFERENCE

ROCKAWAY, N.J., JUNE 09, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT THE REVIEW ARTICLE, "WITHOUT GETTING UNDER YOUR SKIN: NON-INVASIVE STIMULATION ACTIVATES THE VAGUS NERVE," HAS BEEN ACCEPTED FOR PUBLICATION INFRONTIERS IN NEUROSCIENCE.

FRONTIERS IN NEUROSCIENCE ACCEPTS REVIEW ARTICLE SYNTHESIZING EVIDENCE THAT CERVICAL NVNS ACTIVATES THE VAGUS NERVE WITHOUT SURGERY

ROCKAWAY, N.J., JUNE 02, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC.(NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT IT WILL BE PRESENTING AT PLANET MICROCAP LAS VEGAS 2026 POWERED BY MICROCAPCLUB BEING HELD AT THE BELLAGIO RESORT & CASINO IN LAS VEGAS, NV. JOSHUA LEV, INTERIM PRESIDENT AND CFO, WILL DELIVER A PRESENTATION AND HOST ONE-ON-ONE INVESTOR MEETINGS THROUGHOUT THE CONFERENCE.

ELECTROCORE TO PRESENT AT THE PLANET MICROCAP LAS VEGAS 2026 POWERED BY MICROCAPCLUB

ROCKAWAY, N.J., MAY 13, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THE PUBLICATION OF NEW CLINICAL FINDINGS INJAMA NETWORK OPENTITLED, TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION AND PAIN WITH MOVEMENT IN PEOPLE WITH FIBROMYALGIA: A CLUSTER RANDOMIZED CLINICAL TRIAL.

ELECTROCORE ANNOUNCES PUBLICATION IN JAMA HIGHLIGHTING THE BENEFITS OF ADDING QUELL ELECTRICAL NERVE STIMULATION TO OUTPATIENT PHYSICAL THERAPY IN FIBROMYALGIA

ROCKAWAY, N.J., MAY 08, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR), A COMMERCIAL-STAGE BIOELECTRONIC MEDICINE AND WELLNESS COMPANY, ANNOUNCED TODAY THAT IT WILL BE PARTICIPATING IN THE LD MICRO INVITATIONAL XVI CONFERENCE BEING HELD AT THE LUXE SUNSET BOULEVARD HOTEL IN LOS ANGELES, CA. JOSHUA LEV, INTERIM PRESIDENT AND CFO, WILL DELIVER A PRESENTATION AND HOST ONE-ON-ONE MEETINGS THROUGHOUT THE DAY.

ELECTROCORE TO PRESENT AT THE LD MICRO INVITATIONAL XVI CONFERENCE ON MAY 18, 2026

FIRST QUARTER 2026 NET SALES OF $9.6 MILLION, AN INCREASE OF 43% OVER $6.7 MILLION IN THE FIRST QUARTER 2025 NET LOSS OF $5.3 MILLION WITH ADJUSTED EBITDA NET LOSS IMPROVING 24% FROM PRIOR-YEAR PERIOD TO $2.3 MILLION COMPANY TO HOST A CONFERENCE CALL AND WEBCAST TODAY, MAY 6, 2026, AT 4:30 PM EDT ROCKAWAY, N.J., MAY 06, 2026 (GLOBE NEWSWIRE) -- ELECTROCORE, INC. (NASDAQ: ECOR) (ELECTROCORE OR THE COMPANY), A BIOELECTRONIC TECHNOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

electroCore, Inc.

ECOR

Price

Financial Reports

No items found.

Press Releases

electroCore, Inc.

ECOR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ECOR